Thiazolidinediones--the New Insulin Enhancers
Overview
Authors
Affiliations
Insulin resistance, characterized by reduced responsiveness to normal circulating levels of insulin, leads to hyperglycemia and hyperinsulinemia resulting in a deadly quartet of non-insulin dependent diabetes mellitus, obesity, hypertension and dyslipidemia These complications, also referred to as 'Syndrome X' have been associated with an increased risk of coronary heart disease. A number of non-pharmacological and pharmacological interventions are available for prevention and treatment of insulin resistance. However, introduction of thiazolidinediones, the new orally active class of drug, has proved to be a major breakthrough in this field. These agents have been shown to reduce insulin resistance by a novel mechanism of action. By interacting with a family of nuclear receptors known as peroxisome proliferator activated receptors thiazolidinediones are thought to enhance the actions of insulin, thereby increasing insulin dependent glucose disposal and reducing hepatic glucose output. A series of animal and clinical studies in patients with impaired Glucose Tolerance and NIDDM have demonstrated the safety and effect of various thiazolidinediones including ciglitazone, pioglitazone and troglitazone. Thus, thiazolidinediones by unlocking insulin resistance act as a key to glycemic control and hence are likely to prove a useful and rational therapy in NIDDM and possibly other disorders resulting from insulin resistance.
Long N, Le Gresley A, Wren S ChemMedChem. 2021; 16(11):1716-1735.
PMID: 33844475 PMC: 8251912. DOI: 10.1002/cmdc.202100177.
Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus.
Tafuri K, Godil M, Lane A, Wilson T J Clin Res Pediatr Endocrinol. 2014; 5(4):236-9.
PMID: 24379032 PMC: 3890222. DOI: 10.4274/Jcrpe.981.
Effects of dietary restriction on insulin resistance in obese mice.
Feuers R, Desai V, Chen F, Hunter J, Duffy P, Oriaku E J Am Aging Assoc. 2013; 23(2):95-101.
PMID: 23604843 PMC: 3455787. DOI: 10.1007/s11357-000-0010-0.
Inflammatory responses in the atria: should they stay or should they go?.
Duffy H Heart Rhythm. 2010; 8(2):286-7.
PMID: 21056699 PMC: 3058228. DOI: 10.1016/j.hrthm.2010.11.006.
The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.
Smith N, Stoddart L, Devine N, Jenkins L, Milligan G J Biol Chem. 2009; 284(26):17527-39.
PMID: 19398560 PMC: 2719392. DOI: 10.1074/jbc.M109.012849.